Medical School

  • Johns Hopkins University , Baltimore , MD


  • Johns Hopkins University , Baltimore , MD


  • Johns Hopkins University , Baltimore , MD


  • Boston Children's Hospital , Boston , MA


  • American Board of Pediatrics, Pediatric Pulmonology


Publications powered by Harvard Catalyst Profiles

  1. Bartley BL, Schwartz CE, Stark RB, Georgiopoulos AM, Friedman D, Richards CJ, Dorkin HL, Kinane TB, Neuringer IP, Yonker LM. Lung transplant referral practice patterns: a survey of cystic fibrosis physicians and general pulmonologists. BMC Pulm Med. 2020 Mar 04; 20(1):58. View abstract
  2. Harris C, Katkin J, Cataletto M, Dorkin H, Laskosz L, Ruch-Ross H. US pediatric pulmonology workforce. Pediatr Pulmonol. 2019 04; 54(4):444-450. View abstract
  3. Dorkin HL, Staab D, Operschall E, Alder J, Criollo M. Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis. BMJ Open Respir Res. 2015; 2(1):e000100. View abstract
  4. Gaggar A, Chen J, Chmiel JF, Dorkin HL, Flume PA, Griffin R, Nichols D, Donaldson SH. Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis. J Cyst Fibros. 2016 Mar; 15(2):227-33. View abstract
  5. Lee EY, Dorkin H, Vargas SO. Congenital pulmonary malformations in pediatric patients: review and update on etiology, classification, and imaging findings. Radiol Clin North Am. 2011 Sep; 49(5):921-48. View abstract
  6. Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, De Boeck K, Donaldson SH, Dorkin HL, Dunitz JM, Durie PR, Jain M, Leonard A, McCoy KS, Moss RB, Pilewski JM, Rosenbluth DB, Rubenstein RC, Schechter MS, Botfield M, Ordoñez CL, Spencer-Green GT, Vernillet L, Wisseh S, Yen K, Konstan MW. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax. 2012 Jan; 67(1):12-8. View abstract
  7. Hale JE, Parad RB, Dorkin HL, Gerstle R, Lapey A, O'Sullivan BP, Spencer T, Yee W, Comeau AM. Cystic fibrosis newborn screening: using experience to optimize the screening algorithm. J Inherit Metab Dis. 2010 Oct; 33(Suppl 2):S255-61. View abstract
  8. Moss RB, Milla C, Colombo J, Accurso F, Zeitlin PL, Clancy JP, Spencer LT, Pilewski J, Waltz DA, Dorkin HL, Ferkol T, Pian M, Ramsey B, Carter BJ, Martin DB, Heald AE. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum Gene Ther. 2007 Aug; 18(8):726-32. View abstract
  9. O'Sullivan BP, Zwerdling RG, Dorkin HL, Comeau AM, Parad R. Early pulmonary manifestation of cystic fibrosis in children with the DeltaF508/R117H-7T genotype. Pediatrics. 2006 Sep; 118(3):1260-5. View abstract
  10. Shnayderman M, Mansfield B, Yip P, Clark HA, Krebs MD, Cohen SJ, Zeskind JE, Ryan ET, Dorkin HL, Callahan MV, Stair TO, Gelfand JA, Gill CJ, Hitt B, Davis CE. Species-specific bacteria identification using differential mobility spectrometry and bioinformatics pattern recognition. Anal Chem. 2005 Sep 15; 77(18):5930-7. View abstract
  11. Parad RB, Comeau AM, Dorkin HL, Dovey M, Gerstle R, Martin T, O'Sullivan BP. Sweat testing infants detected by cystic fibrosis newborn screening. J Pediatr. 2005 Sep; 147(3 Suppl):S69-72. View abstract
  12. Comeau AM, Parad R, Gerstle R, O'Sullivan BP, Dorkin HL, Dovey M, Haver K, Martin T, Eaton RB. Challenges in implementing a successful newborn cystic fibrosis screening program. J Pediatr. 2005 Sep; 147(3 Suppl):S89-93. View abstract
  13. Comeau AM, Parad R, Gerstle R, O'Sullivan BP, Dorkin HL, Dovey M, Haver K, Martin T, Eaton RB. Communications systems and their models: Massachusetts parent compliance with recommended specialty care after positive cystic fibrosis newborn screening result. J Pediatr. 2005 Sep; 147(3 Suppl):S98-100. View abstract
  14. Comeau AM, Parad RB, Dorkin HL, Dovey M, Gerstle R, Haver K, Lapey A, O'Sullivan BP, Waltz DA, Zwerdling RG, Eaton RB. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. Pediatrics. 2004 Jun; 113(6):1573-81. View abstract
  15. Wheeler PG, Smith R, Dorkin H, Parad RB, Comeau AM, Bianchi DW. Genetic counseling after implementation of statewide cystic fibrosis newborn screening: Two years' experience in one medical center. Genet Med. 2001 Nov-Dec; 3(6):411-5. View abstract
  16. Joseph PM, O'Sullivan BP, Lapey A, Dorkin H, Oren J, Balfour R, Perricone MA, Rosenberg M, Wadsworth SC, Smith AE, St George JA, Meeker DP. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications. Hum Gene Ther. 2001 Jul 20; 12(11):1369-82. View abstract
  17. Perricone MA, Morris JE, Pavelka K, Plog MS, O'Sullivan BP, Joseph PM, Dorkin H, Lapey A, Balfour R, Meeker DP, Smith AE, Wadsworth SC, St George JA. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. II. Transfection efficiency in airway epithelium. Hum Gene Ther. 2001 Jul 20; 12(11):1383-94. View abstract
  18. Redding GJ, Cloutier MM, Dorkin HL, Brotherton SE, Mulvey HJ. Practice of pediatric pulmonology: results of the Future of Pediatric Education Project (FOPE) Pediatr Pulmonol. 2000 Sep; 30(3):190-7. View abstract
  19. Meissner HC, Welliver RC, Chartrand SA, Law BJ, Weisman LE, Dorkin HL, Rodriguez WJ. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Pediatr Infect Dis J. 1999 Mar; 18(3):223-31. View abstract
  20. Eisenberg JD, Aitken ML, Dorkin HL, Harwood IR, Ramsey BW, Schidlow DV, Wilmott RW, Wohl ME, Fuchs HJ, Christiansen DH, Smith AL. Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. J Pediatr. 1997 Jul; 131(1 Pt 1):118-24. View abstract
  21. Jackson AC, Neff KM, Dorkin HL, Lutchen KR. Interpretation of respiratory input impedance in healthy infants. Pediatr Pulmonol. 1996 Dec; 22(6):364-75. View abstract
  22. Stone PJ, Konstan MW, Berger M, Dorkin HL, Franzblau C, Snider GL. Elastin and collagen degradation products in urine of patients with cystic fibrosis. Am J Respir Crit Care Med. 1995 Jul; 152(1):157-62. View abstract
  23. Grubman SA, Fang SL, Mulberg AE, Perrone RD, Rogers LC, Lee DW, Armentano D, Murray SL, Dorkin HL, Cheng SH, et al. Correction of the cystic fibrosis defect by gene complementation in human intrahepatic biliary epithelial cell lines. Gastroenterology. 1995 Feb; 108(2):584-92. View abstract
  24. Ramsey BW, Dorkin HL. Consensus conference: practical applications of Pulmozyme. September 22, 1993. Pediatr Pulmonol. 1994 Jun; 17(6):404-8. View abstract
  25. Ramsey BW, Astley SJ, Aitken ML, Burke W, Colin AA, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Schidlow DV, et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis. 1993 Jul; 148(1):145-51. View abstract
  26. Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, Schidlow DV, Wilmott RW, Astley SJ, McBurnie MA, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med. 1993 Jun 17; 328(24):1740-6. View abstract
  27. Richards B, Skoletsky J, Shuber AP, Balfour R, Stern RC, Dorkin HL, Parad RB, Witt D, Klinger KW. Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum Mol Genet. 1993 Feb; 2(2):159-63. View abstract
  28. Jefferson DM, Valentich JD, Marini FC, Grubman SA, Iannuzzi MC, Dorkin HL, Li M, Klinger KW, Welsh MJ. Expression of normal and cystic fibrosis phenotypes by continuous airway epithelial cell lines. Am J Physiol. 1990 Dec; 259(6 Pt 1):L496-505. View abstract
  29. Lutchen KR, Habib RH, Dorkin HL, Wall MA. Respiratory impedance and multibreath N2 washout in healthy, asthmatic, and cystic fibrosis subjects. J Appl Physiol (1985). 1990 May; 68(5):2139-49. View abstract
  30. Jackson AC, Giurdanella CA, Dorkin HL. Density dependence of respiratory system impedances between 5 and 320 Hz in humans. J Appl Physiol (1985). 1989 Dec; 67(6):2323-30. View abstract
  31. Dorkin HL, Lutchen KR, Jackson AC. Human respiratory input impedance from 4 to 200 Hz: physiological and modeling considerations. J Appl Physiol (1985). 1988 Feb; 64(2):823-31. View abstract
  32. Jackson AC, Lutchen KR, Dorkin HL. Inverse modeling of dog airway and respiratory system impedances. J Appl Physiol (1985). 1987 Jun; 62(6):2273-82. View abstract
  33. Miller K, Gouveia WA, Barza M, Bower K, Curtis L, Decker EL, Dorkin H, Estes M, Mackey W, Marchbein D, et al. Undesirable marketing practices in the pharmaceutical industry. N Engl J Med. 1985 Jul 04; 313(1):54. View abstract
  34. Dorkin HL, Stark AR, Werthammer JW, Strieder DJ, Fredberg JJ, Frantz ID. Respiratory system impedance from 4 to 40 Hz in paralyzed intubated infants with respiratory disease. J Clin Invest. 1983 Sep; 72(3):903-10. View abstract
  35. Schwartz AM, Dorkin HL, Carter BL. CT appearance of the liver in a patient with biliary cirrhosis and cystic fibrosis. J Comput Assist Tomogr. 1983 Jun; 7(3):530-3. View abstract
  36. Dorkin HL, Jackson AC, Strieder DJ, Dawson SV. Interaction of oscillatory and unidirectional flows in straight tubes and an airway cast. J Appl Physiol Respir Environ Exerc Physiol. 1982 Apr; 52(4):1097-1105. View abstract
  37. Fredberg JJ, Wohl ME, Glass GM, Dorkin HL. Airway area by acoustic reflections measured at the mouth. J Appl Physiol Respir Environ Exerc Physiol. 1980 May; 48(5):749-58. View abstract
  38. Caplan LM, Dobson ML, Dorkin H. Yersinia enterocolitica septicemia. Am J Clin Pathol. 1978 Feb; 69(2):189-92. View abstract
  39. Siggers DC, Rogers JG, Boyer SH, Margolet L, Dorkin H, Banerjee SP, Shooter EM. Increased nerve-growth-factor beta-chain cross-reacting material in familial dysautonomia. N Engl J Med. 1976 Sep 16; 295(12):629-34. View abstract
  40. Fisher RA, Turner BM, Dorkin H, Harris H. An investigation of some factors affecting levels of erythrocyte inorganic pyrophosphatase activity. Clin Chim Acta. 1975 May 15; 61(1):27-37. View abstract
  41. Fisher RA, Turner BM, Dorkin HL, Harris H. Studies on human erythrocyte inorganic pyrophosphatase. Ann Hum Genet. 1974 Jan; 37(3):341-53. View abstract